These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 21047207)

  • 41. Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors.
    Nashan B
    Transpl Int; 2004 Jul; 17(6):279-85. PubMed ID: 15221123
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Untreated rejection in 6-month protocol biopsies is not associated with fibrosis in serial biopsies or with loss of graft function.
    Scholten EM; Rowshani AT; Cremers S; Bemelman FJ; Eikmans M; van Kan E; Mallat MJ; Florquin S; Surachno J; ten Berge IJ; Bajema IM; de Fijter JW
    J Am Soc Nephrol; 2006 Sep; 17(9):2622-32. PubMed ID: 16899517
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
    Hernández D; Miquel R; Porrini E; Fernández A; González-Posada JM; Hortal L; Checa MD; Rodríguez A; García JJ; Rufino M; Torres A
    Transplantation; 2007 Sep; 84(6):706-14. PubMed ID: 17893603
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Exploring treatment options in renal transplantation: the problems of chronic allograft dysfunction and drug-related nephrotoxicity.
    Campistol JM; Grinyó JM
    Transplantation; 2001 Jun; 71(11 Suppl):SS42-51. PubMed ID: 11583488
    [TBL] [Abstract][Full Text] [Related]  

  • 45. FK506 nephrotoxicity.
    Finn WF
    Ren Fail; 1999; 21(3-4):319-29. PubMed ID: 10416209
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunosuppressant-induced nephropathy: pathophysiology, incidence and management.
    Olyaei AJ; de Mattos AM; Bennett WM
    Drug Saf; 1999 Dec; 21(6):471-88. PubMed ID: 10612271
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Does Mineralocorticoid Receptor Antagonism Prevent Calcineurin Inhibitor-Induced Nephrotoxicity?
    Mortensen LA; Bistrup C; Thiesson HC
    Front Med (Lausanne); 2017; 4():210. PubMed ID: 29226122
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cellular mechanisms of vascular injury mediated by calcineurin inhibitors.
    Lamas S
    Kidney Int; 2005 Aug; 68(2):898-907. PubMed ID: 16014073
    [No Abstract]   [Full Text] [Related]  

  • 49. Cyclosporine nephrotoxicity.
    Burdmann EA; Andoh TF; Yu L; Bennett WM
    Semin Nephrol; 2003 Sep; 23(5):465-76. PubMed ID: 13680536
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Calcineurin inhibitor-mediated bilateral hippocampal injury after bone marrow transplantation.
    Lee SH; Kim BC; Yang DH; Park MS; Choi SM; Kim MK; Cho KH
    J Neurol; 2008 Jun; 255(6):929-31. PubMed ID: 18458866
    [No Abstract]   [Full Text] [Related]  

  • 51. Calcineurin inhibitor induced nephrotoxicity in steroid resistant nephrotic syndrome.
    Sinha A; Sharma A; Mehta A; Gupta R; Gulati A; Hari P; Dinda AK; Bagga A
    Indian J Nephrol; 2013 Jan; 23(1):41-6. PubMed ID: 23580804
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nephrotoxicity of Calcineurin Inhibitors in Kidney Epithelial Cells is Independent of NFAT Signaling.
    Karolin A; Escher G; Rudloff S; Sidler D
    Front Pharmacol; 2021; 12():789080. PubMed ID: 35140605
    [No Abstract]   [Full Text] [Related]  

  • 53. A Review on Drug-Induced Nephrotoxicity: Pathophysiological Mechanisms, Drug Classes, Clinical Management, and Recent Advances in Mathematical Modeling and Simulation Approaches.
    Mody H; Ramakrishnan V; Chaar M; Lezeau J; Rump A; Taha K; Lesko L; Ait-Oudhia S
    Clin Pharmacol Drug Dev; 2020 Nov; 9(8):896-909. PubMed ID: 33025766
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Electrolyte and Acid-base disturbances induced by clacineurin inhibitors.
    Lee CH; Kim GH
    Electrolyte Blood Press; 2007 Dec; 5(2):126-30. PubMed ID: 24459511
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The epidemiology of drug-induced disorders: the kidney.
    Taber SS; Pasko DA
    Expert Opin Drug Saf; 2008 Nov; 7(6):679-90. PubMed ID: 18983215
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The use of urinary enzymes as markers of nephrotoxicity.
    Dubach UC; Le Hir M; Gandhi R
    Pol Arch Med Wewn; 1988 Nov; 80(5):283-9. PubMed ID: 3078211
    [No Abstract]   [Full Text] [Related]  

  • 57. [(Immuno‑)Pathology of drug side effects in the kidney].
    Pfister F; Büttner-Herold M; Amann K
    Pathologe; 2018 Nov; 39(6):576-582. PubMed ID: 30167781
    [TBL] [Abstract][Full Text] [Related]  

  • 58. AJKD Atlas of Renal Pathology: Calcineurin Inhibitor Nephrotoxicity.
    Lusco MA; Fogo AB; Najafian B; Alpers CE
    Am J Kidney Dis; 2017 May; 69(5):e21-e22. PubMed ID: 28434526
    [No Abstract]   [Full Text] [Related]  

  • 59. Drug-induced acute kidney injury.
    Schetz M; Dasta J; Goldstein S; Golper T
    Curr Opin Crit Care; 2005 Dec; 11(6):555-65. PubMed ID: 16292059
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chronic progressive calcineurin nephrotoxicity: an overstated concept.
    Matas AJ
    Am J Transplant; 2011 Apr; 11(4):687-92. PubMed ID: 21446973
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.